Gilead's antiviral meets main goal of trial in coronavirus patients
In that trial, Gilead said 62% of patients treated early with remdesivir were discharged from the hospital, compared with 49% of patients who were treated late.
An ampule of drug Remdesivir is pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany, April 8, 2020, as the spread of coronavirus disease (COVID-19) continues(photo credit: ULRICH PERREY/POOL VIA REUTERS)ByREUTERS
